Preclinical characterization of GDC-0077, a specific PI3K alpha inhibitor in early clinical development

被引：7
|
作者：
Edgar, Kyle
Hanan, Emily
Staben, Steven
Schmidt, Stephen
Hong, Rebecca
Song, Kyung
Young, Amy
Hamilton, Patricia
Arrazate, Alfonso
de la Cruz, Cecile
Belvin, Marcia
Nannini, Michelle
Friedman, Lori S.
Sampath, Deepak
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-156
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
156
引用
收藏
页数：2
相关论文
共 50 条
  • [41] GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
    Wallin, Jeffrey J.
    Edgar, Kyle A.
    Guan, Jane
    Berry, Megan
    Prior, Wei Wei
    Lee, Leslie
    Lesnick, John D.
    Lewis, Cristina
    Nonomiya, Jim
    Pang, Jodie
    Salphati, Laurent
    Olivero, Alan G.
    Sutherlin, Daniel P.
    O'Brien, Carol
    Spoerke, Jill M.
    Patel, Sonal
    Lensun, Letitia
    Kassees, Robert
    Ross, Leanne
    Lackner, Mark R.
    Sampath, Deepak
    Belvin, Marcia
    Friedman, Lori S.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2011, 10 (12) : 2426 - 2436
  • [42] Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
    Hua-fu Zhao
    Jing Wang
    Wei Shao
    Chang-peng Wu
    Zhong-ping Chen
    Shing-shun Tony To
    Wei-ping Li
    [J]. Molecular Cancer, 16
  • [43] Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
    Zhao, Hua-fu
    Wang, Jing
    Shao, Wei
    Wu, Chang-peng
    Chen, Zhong-ping
    To, Shing-shun Tony
    Li, Wei-ping
    [J]. MOLECULAR CANCER, 2017, 16
  • [44] Development of PI3K inhibitors: lessons learned from early clinical trials
    Jordi Rodon
    Rodrigo Dienstmann
    Violeta Serra
    Josep Tabernero
    [J]. Nature Reviews Clinical Oncology, 2013, 10 : 143 - 153
  • [45] Development of PI3K inhibitors: lessons learned from early clinical trials
    Rodon, Jordi
    Dienstmann, Rodrigo
    Serra, Violeta
    Tabemero, Josep
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2013, 10 (03) : 143 - 153
  • [46] Radiosensitisation properties of PI3K/AKT inhibitor GDC-0941 in prostate cancer cells
    Floyd, R.
    McDermott, N.
    Meunier, A.
    Marignol, L.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S572 - S572
  • [47] Early preclinical development of PQR309, a novel balanced dual PI3K/mTOR inhibitor for treatment of various cancer types
    Ettlin, R.
    Dieterle, W.
    Fabbro, D.
    Hebeisen, P.
    Beaufils, F.
    Hillmann, P.
    Stumm, M.
    Dimitrijevic, S.
    Wymann, M.
    Cmiljanovic, N.
    Giese, B.
    Cmiljanovic, V.
    [J]. TOXICOLOGY LETTERS, 2015, 238 (02) : S337 - S338
  • [48] Combination Therapy of the Novel PI3K Inhibitor GDC-0941 and Dual PI3K/mTOR Inhibitor GDC-0980 with Trastuzumab-DM1 Antibody Drug Conjugate Enhances Anti-Tumor Activity in Preclinical Breast Cancer Models In Vitro and In Vivo
    Sampath, D.
    Fields, C.
    Li, G.
    Prior, W. W.
    Parsons, K.
    Friedman, L. S.
    Lewis-Phillips, G. D.
    [J]. CANCER RESEARCH, 2010, 70
  • [49] Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3Kδ
    Allen, Rodger A.
    Brookings, Daniel C.
    Powell, Mark J.
    Delgado, Jean
    Shuttleworth, Lindsay K.
    Merriman, Mark
    Fahy, Ian J.
    Tewari, Roohi
    Silva, John P.
    Healy, Louise J.
    Davies, Gareth C. G.
    Twomey, Breda
    Cutler, Rona M.
    Kotian, Apoorva
    Crosby, Andrea
    McCluskey, Gillian
    Watt, Gillian F.
    Payne, Andrew
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2017, 361 (03): : 429 - 440
  • [50] Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
    Rewcastle, Gordon W.
    Kolekar, Sharada
    Buchanan, Christina M.
    Gamage, Swarna A.
    Giddens, Anna C.
    Tsang, Kit Y.
    Kendall, Jackie D.
    Singh, Ripudaman
    Lee, Woo-Jeong
    Smith, Greg C.
    Han, Weiping
    Matthews, David J.
    Denny, William A.
    Shepherd, Peter R.
    Jamieson, Stephen M. F.
    [J]. ONCOTARGET, 2017, 8 (29) : 47725 - 47740
12345